Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2006 1
2007 1
2008 1
2009 1
2010 2
2011 1
2013 1
2014 1
2015 1
2016 1
2020 1
2021 1
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide.
Tornatore C, Wiendl H, Lublin AL, Geertsen SS, Chavin J, Truffinet P, Bar-Or A. Tornatore C, et al. Among authors: lublin al. Front Neurol. 2022 Feb 28;13:828616. doi: 10.3389/fneur.2022.828616. eCollection 2022. Front Neurol. 2022. PMID: 35295832 Free PMC article. Review.
Effective anti-Alzheimer Aβ therapy involves depletion of specific Aβ oligomer subtypes.
Knight EM, Kim SH, Kottwitz JC, Hatami A, Albay R, Suzuki A, Lublin A, Alberini CM, Klein WL, Szabo P, Relkin NR, Ehrlich M, Glabe CG, Gandy S, Steele JW. Knight EM, et al. Among authors: lublin a. Neurol Neuroimmunol Neuroinflamm. 2016 May 10;3(3):e237. doi: 10.1212/NXI.0000000000000237. eCollection 2016 Jun. Neurol Neuroimmunol Neuroinflamm. 2016. PMID: 27218118 Free PMC article.
Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial.
Kuhle J, Chitnis T, Banwell B, Tardieu M, Arnold DL, Rawlings AM, Geertsen SS, Lublin AL, Saubadu S, Truffinet P, Kappos L. Kuhle J, et al. Among authors: lublin al. Mult Scler. 2023 Mar;29(3):385-394. doi: 10.1177/13524585221144742. Epub 2023 Jan 12. Mult Scler. 2023. PMID: 36632983 Free PMC article. Clinical Trial.
Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study.
Miller AE, Olsson TP, Wolinsky JS, Comi G, Kappos L, Hu X, Xu X, Lublin AL, Truffinet P, Chavin J, Delhay JL, Benamor M, Purvis A, Freedman MS; TOWER investigators. Miller AE, et al. Among authors: lublin al. Mult Scler Relat Disord. 2020 Nov;46:102438. doi: 10.1016/j.msard.2020.102438. Epub 2020 Aug 1. Mult Scler Relat Disord. 2020. PMID: 32911306 Clinical Trial.
15 results